Colorectal cancer (CRC) is the second most common cancer in women and the third most common in men worldwide[@b1]. In 2012, the World Health Organization estimated that about 1,360,000 new CRC cases occurred worldwide. In addition, 694,000 deaths from CRC were estimated worldwide, accounting for 8.5% of all cancer deaths, and making CRC the fourth most common cause of death from cancer[@b2]. Although the relative 5-year survival rate of European CRC patients increased between 1930 and 2010[@b3], that 5-year survival rate was only 30--65% worldwide[@b4].

Genetic susceptibility has a well-established role in the etiology of CRC[@b5][@b6]. Accumulating evidence supports the hypothesis that copy number variation (CNV) is a molecular biomarker for CRC risk and prognosis[@b7]. DNA CNVs, as structural variants, can be small: microscopic or submicroscopic; or they can be large: deletions, duplications or insertions, often larger than 1 kb[@b8][@b9].

CNVs in the E3 ubiquitin ligases (E3) of the ubiquitin-proteasome system (UPS) have been associated with CRC risk and prognosis[@b10][@b11][@b12]. E3 plays a critical role in the specific protein degradation of UPS, which has an essential regulatory role in cell cycle progression, cell proliferation, differentiation, apoptosis, angiogenesis and cell signaling pathways[@b13][@b14]. The two main subfamilies of E3s are RING and HECT domain containing E3s[@b15]. As members of RING E3s, *FBXW7, MDM2, SKP2* and *β-TRCP* have been associated with abnormal expression in some malignancies including blood, breast, colon and prostate[@b16][@b17][@b18][@b19]. As a HECT E3 ligase, *NEDD4-1* was also proposed to play a vital role in a number of human cancers, including CRC[@b20][@b21].

*FBXW7* serves as a tumor suppressor gene (*p53*-dependent)[@b22], and loss of *FBXW7* has been associated with CRC risk and poor prognosis[@b23]. *MDM2*, functioning as an oncogene, is amplified in approximately one-third of all human carcinomas including CRC[@b24]. Increased expression of *SKP2* has been significantly associated with poor tumor differentiation and poor prognosis in CRC[@b18]. Overexpression of *β-TRCP* has also been observed in many tumors, such as CRC[@b25], pancreatic cancer[@b26], and breast cancer[@b27]. *NEDD4-1*, as a HECT E3 ligase, is highly expressed in both colorectal and gastric tumor tissues[@b20].

Studies of the CNVs of *FBXW7, MDM2, SKP2, β-TRCP* and *NEDD4-1* genes are mainly limited to intestinal cancer cell lines and clinical pathological tissues[@b10][@b11][@b12][@b19][@b23][@b25][@b28][@b29][@b30][@b31][@b32]. In addition, most studies focus on gene expression; the impact of germline CNVs of these five genes on CRC risk and prognosis are not fully understood. Therefore, we conducted a case-control study to explore associations between the CNVs of *FBXW7, MDM2, SKP2, β-TRCP* and *NEDD4-1* genes and CRC risk. We also followed up with cases to study the association between the CNVs of these five genes and CRC prognosis in China.

Results
=======

Characteristics of study subjects
---------------------------------

The basic characteristics of the 518 CRC patients and the 518 gender, age, and residence matched controls are summarized in [Table 1](#t1){ref-type="table"}. However, 32 pairs of our samples were unable to be genotyped in one of the five genes, so gender was not equally distributed in cases and controls (*P* = 0.002). Education (*P* \< 0.001), occupation (*P* \< 0.001) and family history of other cancers (*P* \< 0.001) were also differently distributed in cases and controls. Of the 518 CRC cases, 262 (57.8%) were colon cancer, 191 (42.2%) were rectal cancer. Gender, occupation, education and family history of cancer were adjusted in the following analysis.

Copy number variation and CRC risk
----------------------------------

The *FBXW7, MDM2, SKP2, β-TRCP,* and *NEDD4-1* CNVs were in Hardy-Weinberg equilibrium in all controls. [Table 2](#t2){ref-type="table"} shows the CNV frequencies of the five genes and the relationship between the CNVs of the five genes and CRC risk.

We observed significant associations between *MDM2* amplification and increased CRC risk (amp *v.s.* wt: OR~adjusted~ = 14.37, 95% CI: 1.27, 163.74, *P* = 0.032; amp *v.s.* del + wt: OR~adjusted~ = 14.40, 95% CI: 1.26, 164.81, *P* = 0.032). We observed marginally significant association between *SKP2* deletions and CRC risk (del *v.s.* wt: OR~adjusted~ = 0.32, 95% CI: 0.10, 1.00, *P* = 0.050). While there was no significant association between *SKP2* amplification and CRC risk in the amp *v.s.* del + wt model (amp *v.s.* del + wt model: OR = 0.33, 95% CI: 0.11, 1.02, *P* = 0.055). However, we observed no significant associations between *FBXW7, β-TRCP* or *NEDD4-1* CNVs and CRC risk.

Abnormal copy number additive model and CRC risk
------------------------------------------------

In the abnormal copy number additive model, *MDM2* CNVs are significantly associated with increased CRC risk (del + amp *v.s.* wt: OR~adjusted~ = 6.35, 95% CI: 1.67, 24.19, *P* = 0.007). In the additive models, *SKP2* CNVs also significantly decrease CRC risk (del + amp *v.s.* wt: OR~adjusted~ = 0.32, 95% CI: 0.14, 0.72, *P* = 0.006).

Gene-environment interactions on CRC risk
-----------------------------------------

We find a significant synergistic interaction effect between *SKP2* CNVs and fruit consumption (amp *v.s.* del + wt: OR~i~ = 13.89, 95% CI: 1.20, 160.57, *P* = 0.035) ([Table 3](#t3){ref-type="table"}). In addition, there is a significant interaction effect between the amplification of *SKP2* and roughage consumption (≥50 g/week) (amp *v.s.* del + wt: OR~eg~ = 0.18, 95% CI: 0.03, 0.99). We also find significant interaction effects between the amplification of *FBXW7* and consumption of roughage (≥50 g/week) or fish (\>once/week) (OR~eg~ = 0.37, 95% CI: 0.15, 0.91 and OR~eg~ = 0.25, 95% CI: 0.07, 0.94, respectively). There were also significant interaction effects between the amplification of *NEDD4-1* and consumption of refined grains (\>250 g/week) (OR~eg~ = 2.83, 95% CI: 1.02, 7.88), Chinese pickled sour cabbage (\>twice/month) (OR~eg~ = 3.59, 95% CI: 1.23, 10.48), and fatty meats (OR~eg~ = 3.60, 95% CI: 1.27, 10.19).

Gene-environment interactions in abnormal copy number additive model
--------------------------------------------------------------------

We observed significant synergistic interactions between *SKP2* del + amp genotype and fish intake on CRC risk (del + amp *v.s.* wt: OR~i~ = 13.62, 95% CI: 1.70, 109.36, *P* = 0.014) ([Table 3](#t3){ref-type="table"}). In addition, We also observed significant interaction effects between the del + amp genotype of *SKP2* and roughage consumption (≥50 g/week), or fruit (≥twice/week) consumption (del + amp *v.s.* wt: OR~eg~ equal to 0.13 (95% CI: 0.04, 0.44) and 0.33 (95% CI: 0.12, 0.96), respectively). We also find significant interaction effects between the del + amp genotype of *MDM2* and consumption of refined grains (\>250 g/week) (OR~eg~ = 5.44, 95% CI: 1.03, 28.86), fatty meats (OR~eg~ = 8.55, 95% CI: 1.22, 59.75), eggs (\>3/week) (OR~eg~ = 7.33, 95% CI: 1.57, 34.30), Chinese pickled sour cabbage (\>twice/month) (OR~eg~ = 27.61, 95% CI: 2.12, 259.81) and leftovers (\>3 times/week) (OR~eg~ = 26.67, 95% CI: 2.62, 271.60). Moreover, we observed a significant interaction between *FBXW7* CNVs and pork consumption (\>250 g/week) (del + amp *v.s.* wt: OR~i~ = 3.13, 95% CI: 1.06, 9.41, *P* = 0.040). We find significant interaction effects between the del + amp genotype of *FBXW7* and consumption of refined grains (\>250 g/day), fatty meats and physical exercise (OR~eg~ = 2.81 (95% CI: 1.52, 6.86), OR~eg~ = 2.30 (95% CI: 1.03, 5.11) and OR~eg~ = 0.06 (95% CI: 0.01, 0.31), respectively). Finally, we also find significant interaction effects between the del + amp genotype of *NEDD4-1* and consumption of refined grains (\>250 g/day), fatty meats and physical exercise (OR~eg~ = 2.75 (95% CI: 1.00, 7.55) OR~eg~ = 3.30 (95% CI: 1.21, 9.14) and OR~eg~ = 0.06 (95% CI: 0.01, 0.31), respectively).

Copy number variations and CRC prognosis
----------------------------------------

323 patients completed the follow-up ([Table 4](#t4){ref-type="table"}). Of the 323 patients, 186 (57.9%) patients didn't receive chemotherapy, 45 (14.0%) patients received FOXFOX4-based chemotherapy, 22 (6.9%) received XELOX-based chemotherapy, 44 (13.7%) received LCF-based chemotherapy, 6 (1.9%) received 5-Fu-based chemotherapy and 18 (5.6%) received other chemotherapy treatments after surgery. The mean overall survival (OS) of CRC patients was 75.35 ± 2.26 months. The CEA and CA19-9 level before surgery, Dukes stage, pathological type and metastasis were adjusted for in the analysis of *FBXW7, MDM2, SKP2, β-TRCP* and *NEDD4-1* CNVs and CRC prognosis, due to their significant association with CRC prognosis in the univariate Cox proportional hazards regression.

We find a marginally significant association between *β-TRCP* CNVs and CRC prognosis (amp *v.s*. wt, HR~adjusted~ = 0.42, 95% CI: 0.19, 0.97, *P* = 0.050). In the additive model, *β-TRCP* CNVs (del + amp) is significantly associated with CRC prognosis (del + amp *v.s.* wt, HR~adjusted~ = 0.39, 95% CI: 0.17, 0.88, *P* = 0.023) ([Table 5](#t5){ref-type="table"}, [Fig. 1a](#f1){ref-type="fig"},b). In the stratified analyses based on tumor location, the significant association between *β-TRCP* CNVs and CRC prognosis becomes marginally significant in rectal cancer (amp *v.s*. wt: HR~adjusted~ = 0.22, 95% CI: 0.06, 0.86, *P* = 0.029; amp *v.s*. del + wt,: HR~adjusted~ = 0.22, 95% CI: 0.06, 0.86, *P* = 0.029; del + amp *v.s.* wt: HR~adjusted~ = 0.21, 95% CI: 0.06, 0.83, *P* = 0.026), but not significant in colon cancer ([Table 5](#t5){ref-type="table"}, [Fig. 1c](#f1){ref-type="fig"}--e). There was no statistically significant association between other gene CNVs and colon or rectal cancer in analyses stratified by tumor location ([Table 5](#t5){ref-type="table"}).

Discussion
==========

To our knowledge, this is the first study on the association between germline CNVs of *FBXW7, MDM2, SKP2, β-TRCP, NEDD4-1* and CRC risk and prognosis. In this study, *MDM2* CNVs significantly increase CRC risk, while *SKP2* CNVs significantly decrease CRC risk. We find evidence of three significant gene-environment interactions that increase risk of CRC: *SKP2* CNVs interact with consumption of fruit and fish consumption, and *FBXW7* CNVs interact with pork consumption. We also observe a significant association between *β-TRCP* CNVs and CRC prognosis.

We observe a significant association between *MDM2* amplification CNVs and CRC risk. However, there are few *MDM2* amplification among patients and controls (9 and 2 respectively), which limits statistical power. Because both amplification and deletion of MDM2 can increase CRC risk, the del + amp *v.s.* wt model can be viewed as a conservative estimate of the effect of *MDM2* on CRC risk. The amplification of *MDM2* may increase CRC risk by up to 14.40-fold, and the del + amp genotype of *MDM2* may also increase CRC risk by 6.35-fold. *MDM2* amplification was observed in 26 of 284 (9%) colorectal cancer tissue samples[@b33], 14 of 80 (18%) CRCs tumor tissue samples[@b34] and almost one-third of sarcomas[@b16]. *MDM2* could promote tumorigenesis by acting as a positive regulator of *p53* or independent of *p53*[@b35]. SNP data also indicate that even small differences in *MDM2* levels may affect cancer risk[@b36]. Moreover, *MDM2* also acts as a tumor suppressor through the Akt pathway, inducing the ubiquitination and degradation of *NFAT* (an invasion-promoting factor), thereby blocking cancer cell motility and invasion[@b37]. This could explain the significant association between *MDM2* CNVs and increased CRC risk in the del + amp *v.s.* wt model in our study. There is no significant association between *MDM2* CNVs and CRC prognosis. The role of *MDM2* in cancer prognosis is controversial, and may be affected by tumor variety and racial differences[@b31][@b38][@b39].

We observed that *SKP2* CNVs (del + amp) are significantly associated with a 68% decreased risk of CRC. The overexpression of *SKP2* was associated with tumor differentiation, malignant transformation, and prognosis of malignant tumors[@b11][@b18]. *SKP2* gene amplification is commonly observed in metastatic tumors but not in early stage cancers[@b18][@b40]. Thus *SKP2* gene amplification is likely to be associated with advanced tumor progression. In our study, 60.9% of CRC patients were in stage I or II ([Table 1](#t1){ref-type="table"}). This may explain the non-significance of the association between *SKP2* CNVs and CRC risk. We did observe significant interactions between *SKP2* CNVs and fish or fruit consumption. Fish consumption has been reported to have protective effects in CRC[@b41], which may be attributable to the omega-3 polyunsaturated fatty acids (PUFAs) in fish[@b42]. Omega-3s function as an anti-inflammatory, and is expected to have a function analogous to aspirin. Aspirin has been shown to reduce the incidence of CRC in both observational studies and randomized trials[@b43][@b44]. Dietary fiber in fruit is hypothesized to reduce the risk of CRC. Potential mechanisms for the protective effect dietary fibers include dilution of fecal carcinogens, reduction of transit time of feces through the bowel, and increased production of short chain fatty acids[@b45][@b46][@b47].

*FBXW7* serves as a substrate adaptor for SCF ubiquitin ligase complex and mediates the recognition and binding of substrate proteins. SCF^*FBXW7*^ degrades several proteins with important roles in cell growth, proliferation, differentiation, and survival[@b48]. Previous studies have reported a tumor-suppressive function of *FBXW7* in colorectal tumor cells or tissues[@b23][@b30], and copy number loss of *FBXW7* gene in tumor tissue was reported to be significantly associated with worse CRC prognosis[@b23]. The blood level of *FBXW7* expression has also been associated with the prognosis of breast cancer patients[@b49]. However, we did not observe any significant association between *FBXW7* CNVs and CRC risk or prognosis. The study by Chang *et al*. also found a non-significant association between *FBXW7* mRNA expression and CRC risk[@b10], which is consistent with our results. About 6% of tumors harbor *FBXW7* loss-of-function variants, with different variants detected in different tumor types. This might reflect tissue-specific roles of *FBXW7* substrates[@b48]. A significant interaction effect has been observed between *FBXW7*, pork intake, and increased CRC risk. An updated meta-analysis of all prospective studies showed that the risk of CRC increased by 29% for every 100 g/d of red meat consumed[@b50]. The hard muscle fibers and high fat content in red meat may be the source of this association.

We found CRC patients with *β-TRCP* CNVs, have a better prognosis with a 58--61% OS increase. *β-TRCP* is the component of the ubiquitin ligase complex targeting *β-catenin* and *NF-ΚB* for proteasome degradation, which may contribute to the inhibition of apoptosis and to tumor metastasis[@b25]. Moreover, enhanced activity of *β-TRCP* has been widely observed in colorectal tumor cells and primary tumors[@b19][@b25]. The dual function of *β-TRCP* might explain the significant association between *β-TRCP* CNVs, and improved CRC prognosis. Different mechanisms of oncogenesis in rectal *vs*. colon cancer may explain why *β-TRCP* CNVs are only associated with rectal cancer prognosis in our study[@b51]. However we do not observe a significant association between *β-TRCP* CNVs and CRC risk. Mutations in *β-TRCP* are rarely detected in CRC, which is consistent with our results[@b52][@b53].

Prior work has indicated that *NEDD4-1* may promote tumorigenesis by decreasing *PTEN* protein level, or through interference with the PI3K/AKT signaling pathway[@b54][@b55]. *NEDD4-1* is overexpressed in cancer cell lines[@b12][@b50], animal models[@b56][@b57][@b58], and in human cancer tissues[@b59][@b60][@b61]. However, we find no significant association between *NEDD4-1* CNVs and CRC risk or prognosis. Meanwhile, there have been no studies focused on the effect of *NEDD4-1* CNVs in peripheral blood on CRC risk and/or prognosis. One study indicated that SCF^*β-TRCP*^ can negatively regulate *NEDD4-1* stability, and *β-TRCP*-mediated destruction of the *NEDD4-1* oncoprotein may inhibit cell proliferation and migration[@b62]. This suggests that epistatic effects between *β-TRCP* and *NEDD4-1* may modify many signaling pathways. Further research is required to shed light on the relationship between these genes, and any differences that may exist between their functions in the germline *vs.* their function in tumor.

As in any case-control or prospective survival study, we must consider the limitations of our study. First, recall bias may be inevitable in the collection of data on environment factors. Second, we collected the frequency of soybean, sausage, fried food, and leftovers consumption without collecting information regarding quantity, which limits the statistical power of our analysis of gene-dietary interactions.

We find that *MDM2* and *SKP2* CNVs are significantly associated with CRC risk. In addition, we observe significant interaction effects between *SKP2* CNVs, fish or fruit consumption, and between *FBXW7* CNVs and pork intake, and CRC risk. There is a significant association between *β-TRCP* CNVs and CRC prognosis. Further research with larger sample sizes and more detailed functional evaluation will be required to confirm our results.

Materials and Methods
=====================

Subjects
--------

After obtaining informed consent from study subjects, and approval from the Institutional Research Board of Harbin Medical University, we carried out the experiment in accordance with the relevant guidelines, including any relevant details. Informed consent was obtained from all subjects. We identified CRC patients who underwent surgery at the Cancer Hospital of Harbin Medical University, based on pathologic diagnosis without pre-selection. We excluded patients with neuroendocrine carcinoma, malignant melanoma, non-Hodgkin's lymphoma, gastrointestinal stromal tumors, and Lynch syndrome CRC. From November 1^st^, 2004 to May 1^st^, 2010, we recruited 518 primary CRC patients. During the same period, we collected cancer free control subjects from the 2nd Affiliated Hospital of Harbin Medical University. We excluded controls with history of gastrointestinal disease according to self-report. 518 controls matched for age, gender, and residence were recruited.

Data collection
---------------

We interviewed each participant face-to-face using a structured questionnaire with questions on demographic characteristics (age, gender, height and weight education and occupation), history of physical exercise, family history of cancer, and dietary status during the 12 months preceding the interview. We collected clinical information from medical records on tumor size, Dukes stage, chemotherapy treatment, histological and pathological types, and level of serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9). We followed up with 323 patients from November 2004 to March 2014. Overall survival (OS) was defined at the primary end point in our study. Survival time was calculated from the date of cancer diagnosis to death from colorectal cancer or other causes, or the time of follow-up. The date and cause of death of CRC patients were validated through the medical certification of death and the Harbin death registration system.

DNA extraction and CNV detection
--------------------------------

We extracted DNA from all 1036 blood samples (518 CRC and 518 controls) using QIAGEN DNeasy Blood & Tissue Kit. We detected *FBXW7, MDM2, SKP2, β-TRCP*, and *NEDD4-1* copy numbers using custom designed TaqMan Copy Number Assays ([Supplementary Table S1](#S1){ref-type="supplementary-material"}). The quantitative assays were performed using the 7500 Fast Real-Time polymerase chain reaction machine in 96-well plates with a 10 ul reaction volume containing 20 ng DNA, 5 ul TaqMan Universal PCR Master Mix, 0.5 ul of the CNV assay, and 0.5 ul of the reference RNase P assay (Applied Biosystems, Carlsbad, Calif). The reaction was completed using the following cycling conditions: 95 °C for 15 seconds and 60 °C for 1 minute for 40 cycles. We used one sample with 2 copies of each CNV as a quality control in every 96-well assay plate ([Supplementary Fig. 1](#S1){ref-type="supplementary-material"}). CNVs for each sample were detected three times. We analyzed data using 7500 software v2.0.6 (Applied Biosystems) to quantify the amplification cycle, and then imported the data to Copy Caller version 2.0 (Applied Biosystems) to estimate the gene copy numbers in every sample.

Statistical analyses
--------------------

We calculated the Hardy-Weinberg equilibrium in controls and compared using Fisher's exact test. We evaluated homogeneity between cases and controls using Student's *t-*test for continuous variables and a Chi-squared test for categorical variables. The unbalanced factors between the two groups were controlled for in a multivariable logistic regression for each gene, and in a multivariable logistic regression for gene-environment interactions. We used odds ratios (OR) and corresponding 95% confidence intervals (95% CI) to estimate the associations between *FBXW7, MDM2, SKP2, β-TRCP* and *NEDD4-1* CNVs and CRC risk via conditional logistic regression. We performed crossover analyses to evaluate gene-environment interaction effects on the risk of CRC with four types of OR (OR~e~, OR~g~, OR~eg~, OR~i~). We adjusted the heterogeneous demography characteristics in the conditional logistic regression. We defined 2 copies as the wild type (wt), more than 2 copies as the amplification type (amp) and less than 2 copies as the deletion type(del). Two additive models were applied in the conditional logistic regression analysis: amp *v.s.* del + wt and del + amp *v.s.* wt to estimate the association between CNVs CRC risk and prognosis. All statistical tests were two-sided, *P* value \< 0.05 in the overall analysis. Adding a Bonferroni correction, a *P* value \< 0.025 was used in stratified analyses. We used a multiple interpolation method to fill missing values in questionnaire responses ([Supplementary Tables S4--S8](#S1){ref-type="supplementary-material"}). All statistical analyses were performed using SAS, version 9.2 (SAS Institute Inc.Cary, NC, USA).
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###### Basic characteristics of cases and controls.

  **Characteristic**                  **No. of Case (%)**   **No. of Controls (%)**   ***P*****value**^**a**^
  ---------------------------------- --------------------- ------------------------- -------------------------
  Age                                    60.45 ± 11.22           59.78 ± 10.64                 0.955
  Gender                                                                                       0.002
   Male                                   299 (57.7)              249 (48.1)                      
   Female                                 219 (42.3)              269 (51.9)                      
  BMI (kg/m^2^)                          23.80 ± 3.80            24.10 ± 4.36                  0.441
  Education^**a**^                                                                            \<0.001
   Primary school and below               288 (58.6)              258 (51.3)                      
   Junior middle school                   103 (21.0)              117 (23.3)                      
   Senior middle school and above         100 (20.4)              128 (25.4)                      
  Occupation^**a**^                                                                           \<0.001
   White collar                            90 (17.9)               64 (12.8)                      
   Blue collar                            260 (51.7)              319 (63.9)                      
   Both                                   153 (30.4)              116 (23.3)                      
  Family history of cancer^**a**^                                                             \<0.001
   Yes                                     38 (10.2)              218 (43.1)                      
   No                                     334 (89.8)              288 (56.9)                      
  Location of primary tumor^**a**^                                                   
   Colon                                  262 (57.8)                                              
   Rectum                                 191 (42.2)                                              
  Stage of Dukes^**a**^                                                              
   I                                       52 (10.6)                                              
   II                                     246 (50.3)                                              
   III                                    159 (32.5)                                              
   IV                                      32 (6.6)                                               
   I+II                                   298 (60.9)                                              
   III+IV                                 191 (39.1)                                              

^a^Missing data on subjects, education 27 cases, 15 controls; occupation, 15 cases, 19 controls; family history of cancer, 146 cases, 12 controls; tumor location, 65 cases.; stage of Dukes, 29 cases. ^b^*P* \< 0.05 was considered statistically significant.

###### Associations between CNVs and the risk of CRC.

  **Gene**               **No. of Cases (%)**   **No. of Controls. (%)**   **Odds Ratio**^**a**^   **95% Confidence Interval**   ***P*****Value**^**b**^
  --------------------- ---------------------- -------------------------- ----------------------- ----------------------------- -------------------------
  *MDM2*                                                                                                                        
   Wt                         487 (96.0)               499 (98.4)                  1.00                                                      
   Del                         11 (2.2)                 6 (1.2)                    3.76                    0.69, 20.61                    0.127
   Amp                         9 (1.8)                  2 (0.4)                  **14.37**              **1.27, 163.74**                **0.032**
  Amp *v.s.* del + wt                                                            **14.40**              **1.26, 164.81**                **0.032**
  Del + amp *v.s*. wt                                                            **6.35**                **1.67, 24.19**                **0.007**
  *SKP2*                                                                                                                        
   Wt                         452 (95.4)               433 (91.4)                  1.00                                                      
   Del                         13 (2.7)                 25 (5.2)                 **0.32**                **0.10, 1.00**                 **0.050**
   Amp                         9 (1.9)                  16 (3.4)                   0.32                    0.10, 1.01                     0.052
  Amp *v.s.* del + wt                                                              0.33                    0.11, 1.02                     0.055
  Del + amp *v.s.* wt                                                            **0.32**                **0.14, 0.72**                 **0.006**
  *FBXW7*                                                                                                                       
   Wt                         410 (84.9)               400 (82.8)                  1.00                                                      
   Del                         37 (7.7)                 36 (7.5)                   1.29                    0.61, 2.70                     0.506
   Amp                         36 (4.4)                 7 (9.7)                    0.64                    0.34, 1.23                     0.181
  Amp *v.s.* del + wt                                                              0.63                    0.33, 1.20                     0.162
  Del + amp *v.s.* wt                                                              0.82                    0.52, 1.42                     0.557
  *β-TRCP*                                                                                                                      
   Wt                         465 (93.2)               469 (93.8)                  1.00                                                      
   Del                         5 (1.0)                  8 (1.6)                    0.71                    0.11, 4.41                     0.710
   Amp                         29 (5.8)                 23 (4.6)                   1.59                    0.72, 3.52                     0.252
  Amp *v.s.* del + wt                                                              1.59                    0.72, 3.51                     0.254
  Del + amp *v.s.* wt                                                              1.40                    0.70, 2.88                     0.363
  *NEDD4-1*                                                                                                                     
   Wt                         431 (89.0)               448 (92.6)                  1.00                                                      
   Del                         2 (0.4)                  6 (1.2)                    0.59                    0.08, 4.55                     0.614
   Amp                        51 (10.6)                 30 (6.2)                   1.44                    0.73, 2.87                     0.297
  Amp *v.s.* del + wt                                                              1.44                    0.72, 2.87                     0.297
  Del + amp *v.s.* wt                                                              1.31                    0.39, 2.51                     0.409

^a^Adjusted for gender, occupation, education, and family history of cancer. ^b^*P* \< 0.05 in the conditional logistic regression analysis was considered statistically significant.

###### Interactions between five gene CNVs and environmental factors on the risk of CRC.

  **CNV genotypes**    **Environmental factors**                **Interaction**                                                                    
  ------------------- --------------------------- -------------------------------------------- --------------------------- ----------------------- --------------
  *SKP2*                                                       Roughage (g/week)                                                                          
                                                                      \<50                                 ≥50                                            
                                                               OR~eg~ (95% CI)^a^                                             OR~i~ (95% CI)^a^     *P* value^b^
                               Del + wt                               1.00                          0.58 (0.39, 0.88)                                     
                                  Amp                          0.18 (0.03, 0.98)                  **0.18 (0.03, 0.99)**      1.72 (0.16, 18.74)        0.657
                                  Wt                                  1.00                          0.62 (0.41, 0.94)                                     
                               Del + amp                       0.28 (0.08, 1.00)                  **0.13 (0.04, 0.44)**       0.74 (0.13, 4.30)        0.734
                                                               Fruit (times/week)                                                                         
                                                                      \<2                                  ≥2                                             
                                                               OR~eg~ (95% CI)^a^                                             OR~i~ (95% CI)^a^     *P* value^b^
                               Del + wt                               1.00                          0.61 (0.40, 0.94)                                     
                                  Amp                          0.82 (0.03, 0.53)                    0.70 (0.15, 3.22)       13.89 (1.20, 160.57)       0.035
                                  Wt                                  1.00                          0.62 (0.34, 0.98)                                     
                               Del + amp                       0.09 (0.02, 0.44)                  **0.33 (0.12, 0.96)**      6.10 (0.92, 40.38)        0.061
                                                               Fish (times/week)                                                                          
                                                                       ≤1                                  \>1                                            
                                                               OR~eg~ (95% CI)^a^                                             OR~i~ (95% CI)^a^     *P* value^b^
                                  Wt                                  1.00                          0.30 (0.17, 0.52)                                     
                               Del + amp                       0.09 (0.03, 0.31)                    0.39 (0.08, 2.00)       13.62 (1.70, 109.36)     **0.014**
  *MDM2*                                                     Refined grains (g/day)                                                                       
                                                                      ≤250                                \>250                                           
                                                               OR~eg~ (95% CI)^a^                                             OR~i~ (95% CI)^a^     *P* value^b^
                                  Wt                                  1.00                          2.53 (1.59, 4.02)                                     
                               Del + amp                      13.35 (2.13, 89.49)                **5.44 (1.03, 28.86)**       0.09 (0.00, 2.14)        0.135
                                                                    Fat meat                                                                              
                                                                       No                                  Yes                                            
                                                               OR~eg~ (95% CI)^a^                                             OR~i~ (95% CI)^a^     *P* value^b^
                                  Wt                                  1.00                          2.30 (1.48, 3.57)                                     
                               Del + amp                      11.25 (1.63, 77.25)                **8.55 (1.22, 59.75)**       0.30 (0.02, 5.09)        0.427
                                                                  Egg (/week)                                                                             
                                                                       ≤3                                  \>3                                            
                                                               OR~eg~ (95% CI)^a^                                             OR~i~ (95% CI)^a^     *P* value^b^
                                  Wt                                  1.00                          1.60 (1.08, 2.37)                                     
                               Del + amp                      9.31 (0.66, 131.06)                **7.33 (1.57, 34.30)**      0.49 (0.02, 10.06)        0.645
                                                   Chinese pickled sour cabbage (times/month)                                                      
                                                                       ≤2                                  \>2                                            
                                                               OR~eg~ (95% CI)^a^                                             OR~i~ (95% CI)^a^     *P* value^b^
                                  Wt                                  1.00                          2.05 (1.35, 3.12)                                     
                               Del + amp                       6.41 (1.16, 35.27)               **27.61 (2.12, 259.81)**     2.10 (0.10, 44.07)        0.633
                                                           leftovers (times/week)^c^                                                               
                                                                       ≤3                                  \>3                                            
                                                               OR~eg~ (95% CI)^a^                                             OR~i~ (95% CI)^a^     *P* value^b^
                                  Wt                                  1.00                        1.873 (1.234, 2.843)                                    
                               Del + amp                       3.30 (0.37, 29.54)               **26.67 (2.62, 271.60)**     4.31 (0.18, 100.81)       0.363
  *FBXW7*                                                      Roughage (g/week)                                                                          
                                                                      \<50                                 ≥50                                            
                                                               OR~eg~ (95% CI)^a^                                              ORi (95% CI)^a^      *P* value^b^
                               Del + wt                               1.00                          0.62 (0.41, 0.95)                                     
                                  Amp                          0.57 (0.22, 1.50)                  **0.37 (0.15, 0.91)**       1.04 (0.30, 3.67)        0.946
                                                               Fish (times/week)                                                                          
                                                                       ≤1                                  \>1                                            
                                                               OR~eg~ (95% CI)^a^                                              ORi (95% CI)^a^      *P* value^b^
                               Del + wt                               1.00                          0.34 (0.24, 0.66)                                     
                                  Amp                          0.64 (0.28, 1.44)                  **0.25 (0.07, 0.94)**       0.99 (0.20, 4.88)        0.993
                                                             Refined grains (g/day)                                                                       
                                                                      ≤250                                \>250                                           
                                                               OR~eg~ (95% CI)^a^                                             OR~i~ (95% CI)^a^     *P* value^b^
                                  Wt                                  1.00                          2.28 (1.37, 3.80)                                     
                               Del + amp                       0.87 (0.45, 1.67)                ****2.81 (1.52, 6.86)****     1.43 (0.49, 4.19)        0.519
                                                                    Fat meat                                                                              
                                                                       No                                  Yes                                            
                                                               OR~eg~ (95% CI)^a^                                             OR~i~ (95% CI)^a^     *P* value^b^
                                  Wt                                  1.00                          2.23 (1.35, 3.68)                                     
                               Del + amp                       0.76 (0.40, 1.47)                  **2.30 (1.03, 5.11)**       1.35 (0.47, 3.82)        0.577
                                                                 Pork (g/week)                                                                            
                                                                      ≤250                                \>250                                           
                                                               OR~eg~ (95% CI)^a^                                             OR~i~ (95% CI)^a^     *P* value^b^
                                  Wt                                  1.00                          1.34 (0.87, 2.06)                                     
                               Del + amp                       0.46 (0.21, 0.99)                    1.92 (0.90, 4.11)       **3.13 (1.06, 9.41)**    **0.040**
                                                               Physical exercise                                                                          
                                                                       No                                  Yes                                            
                                                               OR~eg~ (95% CI)^a^                                             OR~i~ (95% CI)^a^     *P* value^b^
                                  Wt                                  1.00                          0.06 (0.02, 0.20)                                     
                               Del + amp                       1.58 (0.66, 3.78)                  **0.06 (0.01, 0.31)**       0.65 (0.10, 4.47)        0.662
  *NEDD4-1*                                                  Refined grains (g/day)                                                                       
                                                                      ≤250                                \>250                  interaction              
                                                               OR~eg~ (95% CI)^a^                                             OR~i~ (95% CI)^a^     *P* value^b^
                               Del + wt                               1.00                          2.61 (1.61, 4.24)                                     
                                  Amp                          1.63 (0.56, 4.71)                  **2.83 (1.02, 7.88)**       0.67 (0.15, 2.89)        0.587
                                  Wt                                  1.00                          2.63 (1.62, 4.27)                                     
                               Del + amp                        1.48 (0.57,3.86)                  **2.75 (1.00, 7.55)**       0.71 (0.18, 2.81)        0.622
                                                   Chinese pickled sour cabbage (times/month)                                                      
                                                                       ≤2                                  \>2                                            
                                                               OR~eg~ (95% CI)^1^                                             OR~i~ (95% CI)^a^     *P* value^b^
                               Del + wt                               1.00                          1.86 (1.21, 2.85)                                     
                                  Amp                          3.13 (0.92, 10.62)                **3.59 (1.23, 10.48)**       1.79 (0.41, 7.88)        0.444
                                                                    Fat meat                                                                              
                                                                       No                                  Yes                                            
                                                               OR~eg~ (95% CI)^a^                                             OR~i~ (95% CI)^a^     *P* value^b^
                               Del + wt                               1.00                          2.26 (1.43, 3.58)                                     
                                  Amp                          1.03 (0.35, 3.00)                 **3.60 (1.27, 10.19)**       1.54 (0.35, 6.71)        0.564
                                  Wt                                  1.00                          2.27 (1.43, 3.60)                                     
                               Del + amp                       1.00 (0.38, 2.62)                  **3.30 (1.21, 9.14)**       1.46 (0.37, 5.84)        0.590
                                                               Physical exercise                                                                          
                                                                       No                                  Yes                                            
                                                               OR~eg~ (95% CI)^a^                                             OR~i~ (95% CI)^a^     *P* value^b^
                                  Wt                                  1.00                          0.06 (0.02, 0.20)                                     
                               Del + amp                       1.58 (0.66, 3.78)                  **0.06 (0.01, 0.31)**     10.27 (0.60, 177.48)       0.109

^a^Adjusted for gender, occupation, education, and family history of cancer. ^b^*P* \< 0.05 in the conditional logistic regression analysis was considered statistically significant. ^c^ leftovers: leftovers more than 12 hours.

###### Clinical and pathological features of 323 CRC patients.

  **Characteristics**                 **Patients**    **%**
  ---------------------------------- --------------- -------
  Age at diagnosis                                   
   \<50                                    74         22.9
   50--60                                  112        34.7
   60--70                                  91         28.2
   \>70                                    46         14.2
   Mean                               58.58 ± 10.68      
  Median survival time (month)             73            
  Extreme value                          0--109          
  Gender                                             
   Male                                    182        56.3
   Female                                  141        43.7
  Location of primary tumer^a^                       
   Colon                                   108        33.5
   Rectum                                  214        66.5
  CEA level (ng/ul)                                  
   \<5                                     141        43.7
   ≥5                                      182        56.3
  CA19-9 level (U/ml)^a^                             
   \<37                                    240        74.8
   ≥37                                     81         25.2
  Pathological type^a^                               
   Protrude type                           202        64.7
   Infiltrating or ulcerative type         107        34.3
   Others                                   3          1.0
  Anastomat on surgery^a^                            
   Yes                                     228        71.9
   No                                      75         23.7
   Unknown                                 14          4.4
  Stage of Dukes^a^                                  
   I                                       39         12.1
   II                                      142        44.1
   III                                     119        37.0
   IV                                      22          6.8
   I+II                                    181        56.2
   III+IV                                  141        43.8
  Histological type                                  
   Adenocarcinoma                          249        77.1
   Mucinous adenocarcinoma                 63         19.5
   Other types                             11          3.4
  Degree of differentiation                          
   Low                                     49         15.2
   Medium                                  258        79.9
   High                                     3          0.9
   Unknown                                 13          4.0
  Chemotherapy treatment^a^                          
   No                                      186        57.9
   FOLFOX4                                 45         14.0
   XELOX                                   22          6.9
   LCF                                     44         13,7
   5-Fu                                     6          1.9
   Others                                  18          5.6
  Metastasis                                         
   Yes                                     141        43.7
   No                                      182        46.3
  Prognosis                                          
   Death                                   136        42.1
   living                                  146        45.2
   Losing follow-up                        41         12.7

CA19-9, carbohydrate antigen19-9; CEA, carcinoembryonic antigen; CI, confidence interval. ^a^Missing data on subjects, tumor location, one case; CA19-9 level, two cases; pathological type, 11 cases; anastomat on surgery, six cases; stage of Dukes, 22 cases; chemotherapy treatment, 2 cases.

###### The relationships between gene CNVs and prognosis of CRC.

  **CNV Genotypes**      **Total patients (n = 323)**   **P Value**^**b**^   **Colon cancer (n = 108)**   **P Value**^**c**^   **Rectal cancer (n = 214)**   **P Value**^**c**^                                                                                                                                         
  --------------------- ------------------------------ -------------------- ---------------------------- -------------------- ----------------------------- -------------------- ----------- ----- ----- --------------- -------------------- ------- ------------ ----- ------ --------------- ----------------------- -----------
  *FBXW7*                                                                                                                                                                                                                                                                                                               
   Wt                             255 (83.6)                    59                       68                  74.00 (2.53)                 1.00                                    88 (85.4)   62    71    77.32 (4.35)           1.00                  166 (82.5)   58     68    72.48 (3.09)              1                  
   Del                             27 (8.9)                     68                       76                  82.75 (7.61)           0.62 (0.29, 1.33)              0.220          10 (9.7)    48    70    68.95 (11.96)   1.09 (0.41, 2.88)    0.868    17 (8.5)    81     81    90.74 (9.01)      0.31 (0.07, 1.26)       0.100
   Amp                             23 (7.5)                     61                       70                  79.35 (8.18)           0.91 (0.46, 1.83)              0.793           5 (4.9)    20    40    35.40 (12.23)   3.39 (1.03, 11.18)   0.045    18 (9.0)    72     78    89.61 (7.71)      0.48 (0.18, 1.29)       0.146
  Amp *v.s.* del + wt                                                                                                               0.95 (0.48, 1.90)              0.888                                                  3.38 (1.05, 11.12)   0.045                                               0.51 (0.19, 1.38)       0.185
  Del + amp *v.s.* wt                                                                                                               0.75 (0.44, 1.29)              0.299                                                  1.57 (0.74, 3.34)    0.242                                               0.41 (0.18, 0.92)       0.031
  *MDM2*                                                                                                                                                                                                                                                                                                                
   Wt                             298 (94.6)                    60                       68                  74.28 (2.35)                 1.00                                    99 (96.1)   56    68     73.5 (4.18)           1.00                  198 (93.8)   60     69    74.97 (2.84)              1                  
   Del                             9 (2.9)                      67                       67                 75.22 (14.09)           0.72 (0.23, 2.29)              0.580           4 (3.9)    75    75    81.25 (20.59)   0.62 (0.08, 4.61)    0.640    5 (2.4)     60     60    55.40 (13.56)     1.13 (0.27, 4.80)       0.867
   Amp                             8 (2.5)                      61                       61                  60.60 (9.15)           0.80 (0.25, 2.57)              0.707              0                                                                 8 (3.8)     61     61    60.60 (9.15)      0.96 (0.30, 3.13)       0.956
  Amp *v.s.* del + wt                                                                                                               0.81 (0.25, 2.61)              0.727                                                                                                                           0.96 (0.30, 3.11)       0.949
  Del + amp *v.s.* wt                                                                                                               0.76 (0.33, 1.75)              0.517                                                  0.62 (0.08, 4.61)    0.640                                               1.03 (0.40, 2.61)       0.957
  *SKP2*                                                                                                                                                                                                                                                                                                                
   Wt                             284 (95.3)                    60                       70                  75.34 (2.39)                 1.00                                    95 (95.0)   58    69    74.9 (44.23)           1.00                  188 (95.5)   61     70    75.79 (2.90)              1                  
   Del                             6 (2.0)                      50                       67                 68.50 (15.37)           1.31 (0.41, 4.17)              0.658           3 (3.0)    33    67    43.33 (16.85)   3.62 (0.80, 16.31)   0.094    3 (1.5)     67     67    84.00 (15.51)     0.75 (0.10, 5.55)       0.777
   Amp                             8 (2.7)                      42                       42                 50.03 (11.55)           1.39 (0.51, 3.79)              0.526           2 (2.0)                19.50 (3.89)    4.68 (0.57, 38.39)   0.151    6 (3.0)     46     46    53.83 (12.53)     0.99 (0.30, 3.22)       0.985
  Amp *v.s.* del + wt                                                                                                               1.38 (0.50, 3.78)              0.531                                                  4.47 (0.55, 36.48)   0.162                                               0.99 (0.31, 3.22)       0.990
  Del + amp *v.s.* wt                                                                                                               1.35 (0.62, 2.91)              0.447                                                  3.92 (1.13, 3.66)    0.032                                               0.93 (0.33, 2.54)       0.865
  *β-TRCP*                                                                                                                                                                                                                                                                                                              
   Wt                             282 (91.0)                    58                       68                  74.09 (2.42)                 1.00                                    90 (89.1)   58    68    73.97 (4.41)           1.00                  191 (91.8)   59     68    74.47 (2.89)              1                  
   Del                             4 (1.3)                     100                      100                 90.53 (11.69)                                          0.962           3 (3.0)    100   100   86.00 (14.69)                        0.976    1 (0.5)     100   100         79                                   0.971
   Amp                             24 (7.7)                     66                       74                  63.25 (5.44)         **0.42 (0.19, 0.97)**          **0.050**         8 (7.9)    50    75    61.00 (8.08)    0.61 (0.18, 2.03)    0.421    16 (7.7)    74     74    64.01 (7.04)    **0.22 (0.06, 0.86)**   **0.029**
  Amp *v.s.* del + wt                                                                                                               0.44 (0.19, 1.01)              0.052                                                  0.63 (0.19, 2.08)    0.444                                             **0.22 (0.06, 0.86)**   **0.029**
  Del + amp *v.s.* wt                                                                                                             **0.39 (0.17, 0.88)**          **0.023**                                                0.50 (0.16, 1.57)    0.230                                             **0.21 (0.06, 0.83)**   **0.026**
  *NEDD4-1*                                                                                                                                                                                                                                                                                                                   
   Wt                             269 (89.7)                    59                       68                  74.39 (2.46)                 1.00                                    89 (87.9)   56    68    73.35 (4.44)           1.00                  181 (90.5)   60    68.4   75.23 (2.94)              1                  
   Del                             2 (0.6)                      50                       50                 46.00 (23.34)           1.02 (0.14, 7.66)              0.985              0                                                                 2 (1.0)     50     50    46.00 (23.34)     0.85 (0.11, 6.81)       0.878
   Amp                             29 (9.7)                     65                       72                  74.79 (7.61)           0.82 (0.40, 1.70)              0.597          12 (12.1)   58    67    70.83 (12.27)   1.06 (0.41, 2.76)    0.900    17 (8.5)    77     76    70.12 (8.26)      0.73 (0.23, 2.35)       0.595
  Amp *v.s.* del + wt                                                                                                               0.82 (0.40, 1.70)              0.597                                                  1.06 (0.41, 2.76)    0.900                                               0.73 (0.23, 2.35)       0.595
  Del + amp *v.s.* wt                                                                                                               0.84 (0.42, 1.67)              0.620                                                  1.06 (0.41, 2.76)    0.900                                               0.75 (0.27, 2.09)       0.578

CI, confidence interval; HR, hazard ratio; OS, overall survival.

^a^adjusted for CEA and CA19-9 level before surgery, Dukes stage, pathological type and metastasis. ^b^*P* \< 0.05 in the survival analysis was considered statistically significant. ^c^*P* \< 0.025 in the stratified survival analysis by location was considered statistically significant.
